胸苷激酶1在肺癌性胸腔积液及结核性胸膜炎中的表达

doi:10.3877/cma.j.issn.1674-6902.2023.06.009

目的

分析肺癌性胸腔积液(lung cancer pleural effusion)及结核性胸膜炎(tuberculous pleurisy)血清中胸苷激酶1(thymidine kinase 1, TK1)的表达。

方法

选择西部战区总医院及西安市胸科医院2018年12月至2022年12月收治的354例单侧胸腔积液患者为对象，依据出院诊断分为结核性胸膜炎患者161例，肺癌性胸腔积液患者193例。对比分析不同人群及原发疾病血清中TK1的表达。

结果

结核性胸膜炎患者平均年龄大于肺癌性胸腔积液患者(61.77±12.31 vs. 44.39±19.03)岁；TK1年龄<30岁患者中表达量最高(4.54±4.04)pmol/L，不同性别、种族及>30岁中表达差异无统计学意义(P>0.05)，结核性胸膜炎患者TK1的表达高于肺癌性胸腔积液患者(3.89±3.52 vs. 2.92±3.44)pmol/L(P＝0.009)；TK1不同病理类型肺癌中表达差异无统计学意义(P＝0.169)。

结论

TK1在肺部疾病所致胸腔积液中具有表达，表达量与性别、种族无关，年轻患者中呈现高表达，结核性胸膜炎患者中TK1表达量高于肺癌性胸腔积液。

关键词: 胸苷激酶1, 结核性胸膜炎, 支气管肺癌, 胸腔积液

Objective

To explore the expression of thymidine kinase 1(TK1) in patients with lung cancer pleural effusion and tuberculous pleurisy.

Methods

The clinical data of 354 patients with unilateral pleural effusion caused by lung cancer and tuberculous pleurisy were retrospectively collected. There were 161 cases were diagnosed with tuberculous pleurisy and 193 cases with lung cancer pleural effusion. The expression of TK1 in serum of patients with different diseases was compared and analyzed.

Results

The average age of patients in tuberculous pleurisy group was higher than that of the malignant pleural effusion group(61.77±12.31 vs. 44.39±19.03). The expression level of TK1 is the highest in patients younger than 30 years old and there was no significant difference in patients older(4.54±4.04)pmol/L than 30 years, furthermore, the same results were observed among different genders and ethnicities. Although the expression of TK1 in patients with different pathological types of lung cancer had no significant difference(P=0.169), the expression of TK1 in tuberculous pleurisy is higher than lung cancer pleural effusion group(3.89±3.52 vs. 2.92±3.44)pmol/L(P=0.009).

Conclusion

There is a definite expression of TK1 in patients with pleural effusion caused by lung disease and the expression quantity has nothing to do with gender and race, but the higher expression in young patients was observed, and the expression of TK1 in tuberculous pleurisy is higher than lung cancer pleural effusion group. Its specificity in distinguishing the etiology of benign and malignant pleural effusion needs further study.

Key words: Thymidine kinase 1, Tuberculous pleurisy, Bronchogenic carcinoma, Pleural effusion

表1 TK1与患者性别、年龄、民族的Pearson相关性

临床资料	变　量	TK1(pmol/L)	年龄	民族	性别
TK1(pmol/L)	皮尔逊相关性	1	－0.104	0.109^a	0.034
	显著性(双尾)		0.051	0.041	0.519
	个案数	354	354	354	354
年龄	皮尔逊相关性	－0.104	1	－0.142^b	0.015
	显著性(双尾)	0.051		0.007	0.778
	个案数	354	354	354	354
民族	皮尔逊相关性	0.109^a	－0.142^b	1	0.007
	显著性(双尾)	0.041	0.007		0.893
	个案数	354	354	354	354
性别	皮尔逊相关性	0.034	0.015	0.007	1
	显著性(双尾)	0.519	0.778	0.893
	个案数	354	354	354	354

表1 TK1与患者性别、年龄、民族的Pearson相关性

临床资料	变　量	TK1(pmol/L)	年龄	民族	性别
TK1(pmol/L)	皮尔逊相关性	1	－0.104	0.109^a	0.034
	显著性(双尾)		0.051	0.041	0.519
	个案数	354	354	354	354
年龄	皮尔逊相关性	－0.104	1	－0.142^b	0.015
	显著性(双尾)	0.051		0.007	0.778
	个案数	354	354	354	354
民族	皮尔逊相关性	0.109^a	－0.142^b	1	0.007
	显著性(双尾)	0.041	0.007		0.893
	个案数	354	354	354	354
性别	皮尔逊相关性	0.034	0.015	0.007	1
	显著性(双尾)	0.519	0.778	0.893
	个案数	354	354	354	354

表2 结核性胸膜炎与肺癌性胸腔积液TKI表达比较(±s)

胸膜炎及积液类型	例数	TKI(pmol/L)	F值	P值
肺癌性胸腔积液		2.92±3.44	1.699	0.169
鳞癌性	22	2.23±1.88
腺癌性	101	2.89±3.32
小细胞肺癌性	11	1.38±1.67
未分类型	59	3.59±4.32
结核性胸膜炎	161	3.89±3.52
F值		1.083
P值		0.009

表2 结核性胸膜炎与肺癌性胸腔积液TKI表达比较(±s)

胸膜炎及积液类型	例数	TKI(pmol/L)	F值	P值
肺癌性胸腔积液		2.92±3.44	1.699	0.169
鳞癌性	22	2.23±1.88
腺癌性	101	2.89±3.32
小细胞肺癌性	11	1.38±1.67
未分类型	59	3.59±4.32
结核性胸膜炎	161	3.89±3.52
F值		1.083
P值		0.009

1	曾　灏，田攀文. 恶性胸腔积液的诊断研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 247-249.
2	孙美琪，张　薇，郝倩文，等. 肿瘤标志物对良恶性胸腔积液鉴别的研究进展[J]. 实用肿瘤杂志，2020, 35(3): 278-283.
3	乔名坤，崔　超. 血清CA125与NSE在结核性胸膜炎临床诊断及治疗评价中的意义[J]. 医学理论与实践，2020, 33(24): 4186-4187.
4	刘佳琪. 血清TK1检测在非小细胞肺癌诊断中的临床意义[J]. 实用肿瘤杂志，2013, 28(1): 61-63.
5	唐　鹏，彭定辉，陈　薇，等. 肺癌患者胸苷激酶1血清水平分析[J]. 微循环学杂志，2020, 30(2): 60-62.
6	Dang L, Ma H, Hei A, et al. A meta-analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment[J]. Mol Clin Oncol, 2020, 12(5): 440-450.
7	Wei Y, Luo Y, Feng Z, et al. TK1 overexpression is associated with the poor outcomes of lung cancer patients: a systematic review and meta-analysis[J]. Biomarkers in Medicine, 2018, 12(4): 403-413.
8	陈效友. 结核病分类与肺结核诊断卫生行业新标准中关于结核性胸膜炎的解析[J]. 中国防痨杂志，2018, 40(3): 239-242.
9	Jiang Y, Guo L, Han L, et al. Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study[J]. J Cancer Res Clin Oncol, 2023, 149(15): 14271-14282.
10	Li Q, Zhang L, Yang Q, et al. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and-independent manners[J]. Cell Metab, 2023, 35(6): 912-927.
11	Tribukait B, Lundgren PO, Kjellman A, et al. Prediction of overall survival by thymidine kinase 1 combined with prostate-specific antigen in men with prostate cancer[J]. Int J Mol Sci, 2023, 24(6): 5160.
12	Cviic D, Jagarlamudi K, Meglic L, et al. A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer[J]. Cancers (Basel), 2023, 15(5): 1593.
13	Shao C, Wang P, Liao B, et al. Multi-Omics Integration Analysis of TK1 in Glioma: A Potential Biomarker for Predictive, Preventive, and Personalized Medical Approaches[J]. Brain Sci, 2023, 13(2): 230.
14	Wang Y, Cui D, Li D, et al. Clinical Value on Combined Detection of Serum CA724, DKK1, and TK1 in Diagnosis of Gastric Cancer[J]. J Oncol, 2022, 2022: 6941748.
15	Fang X, Ma L, Wang Y, et al. Neutrophil extracellular traps accelerate vascular smooth muscle cell proliferation via Akt/CDKN1b/TK1 accompanying with the occurrence of hypertension[J]. J Hypertens, 2022, 40(10): 2045-2057.
16	Xie H, Guo L, Wang Z, et al. Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate Cancer[J]. Front Genet, 2022, 13: 778850.
17	Lou X, Zhou J, Ma H, et al. The Half-Life of Serum Thymidine Kinase 1 Concentration Is an Important Tool for Monitoring Surgical Response in Patients with Lung Cancer: A Meta-Analysis[J]. Genetic testing and molecular biomarkers, 2017, 21(8): 471.
18	Alegre MM, Weyant MJ, Bennett DT, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer[J]. Anticancer research, 2014, 34(5): 2145.
19	Liu C, Wang J, Zhao L, et al. Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells[J]. Frontiers in Oncology, 2020, 9: 1475.
20	Jaamaa S, Nevala R, Jagarlamudi K, et al. Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas[J]. Anticancer Res, 2022, 42(3): 1509-1515.
21	Zhang C, Ma S, Hao X, et al. Methylation status of TK1 correlated with immune infiltrates in prostate cancer[J]. Front Genet, 2022, 13: 899384.
22	Krishnamurthy J, Luo J, Suresh R, et al. A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis[J]. NPJ Breast Cancer, 2022, 8(1): 35.
23	Zuo S, Wang H, Li L, et al. Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming[J]. Front Oncol, 2022, 12: 802807.
24	Lundgren PO, Tribukait B, Kjellman A, et al. Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer[J]. Prostate, 2022, 82(8): 911-916.
25	Saellstrom S, Sharif H, Jagarlamudi KK, et al. Serum TK1 protein and C-reactive protein correlate to treatment response and predict survival in dogs with hematologic malignancies[J]. Res Vet Sci, 2022, 145: 213-221.
26	Fanelli Giuseppe Nicolò, Scarpitta Rosa, Cinacchi Paola, et al. Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients[J]. J Clin Med, 2021, 10(22): 5416.
27	Chen Z, Guan H, Yuan H, et al. Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report[J]. Oncology letters, 2015, 10(3): 1669-1673.
28	Korkmaz T, Seber S, Okutur K, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer[J]. Biomarkers, 2013, 18(1): 88-94.
29	Nisman B, Nechushtan H, Biran H, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report[J]. J Thorac Oncol, 2014, 9(10): 1568-1572.
30	但小苹，田德兴，肖贞良. 胸苷激酶1在肺癌及慢性阻塞性肺疾病急性加重期患者中的表达情况分析[J]. 中国呼吸与危重监护杂志，2019, 18(4): 318-321.

[1]	成丹, 王骁, 李洪波, 任涛, 王建坤. 肺吸虫病误诊为结核性胸腔积液一例[J]. 中华实验和临床感染病杂志(电子版), 2024, 18(03): 182-186.
[2]	张璇, 高杨, 房雅君, 姚艳玲. 保护性机械通气在肺癌胸腔镜肺段切除术中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 563-567.
[3]	陶银花, 张红杰, 王亚岚, 陈莲, 张珺. 间歇式气压治疗预防肺癌化疗下肢深静脉血栓的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 605-608.
[4]	任甜甜, 张玉慧, 祁玲霞, 朱梅冬, 胡佳. 多学科疼痛管理对胸腔镜肺叶切除术后胸痛及应激反应的影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 630-633.
[5]	林建琴, 孔令敏, 陆银凤, 陈勇, 金凤, 叶磊, 陈方梅. PERMA模式对肺癌患者治疗获益感及生活质量的影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 634-638.
[6]	殷国青, 曾莉, 贺斌峰, 孙芬芬. Rab26负性调控Nrf2增强肺癌耐药细胞对奥希替尼的敏感性[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 349-355.
[7]	邓世君, 刘晓青, 刘权兴. 信息化管理在肺癌围手术期中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 466-468.
[8]	李文娟, 徐兴祥, 卞家蓉. 胸段脊膜膨入胸腔误诊为胸腔积液一例[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 497-498.
[9]	吕欣谕, 李雯, 王娟侠, 邹维, 王艳, 雷杰. 围手术期肺康复训练在胸腔镜肺叶切除术中疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 256-259.
[10]	陈羽霞, 柏佩梅, 芦遥遥. 综合干预对肺癌化疗患者的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 307-309.
[11]	胡航, 陈婷婷, 孙健, 孙云浩, 仇丽敏. 三维重建技术在单操作孔胸腔镜肺段切除术的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 310-312.
[12]	张红军, 顾兴, 赵延军, 柴雅琴, 李文洁, 师佩, 张海涛. 超声引导下胸膜活检与内科胸腔镜活检诊断一致性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 185-188.
[13]	张剑, 卢从华, 李江华, 林采余, 吴迪, 王治国, 聂乃夫, 何勇, 李力. 根据转录组学分析奥希替尼获得性耐药机制的研究[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 195-200.
[14]	杨麦青, 张云香. 胃癌化疗后浆膜腔大B细胞淋巴瘤一例报道并文献复习[J]. 中华诊断学电子杂志, 2024, 12(03): 183-187.
[15]	王海珍, 马永明, 姚可盈. 尿激酶治疗结核性包裹性胸腔积液疗效的系统评价与荟萃分析[J]. 中华胸部外科电子杂志, 2024, 11(01): 53-61.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expression of thymidine kinase 1 in patients with lung cancer pleural effusion and tuberculous pleurisy

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expression of thymidine kinase 1 in patients with lung cancer pleural effusion and tuberculous pleurisy